Login to Your Account

Diving further into immuno-oncology, Ono and BMS ink deal for EP4 antagonist

By Cornelia Zou
Staff Writer

Tuesday, December 19, 2017

HONG KONG – Japan-based Ono Pharmaceutical Co. Ltd. entered a license agreement with Bristol-Myers Squibb Co. for the development and commercialization of its compound, ONO-4578, a selective antagonist of EP4, a prostaglandin E2 (PGE2) receptor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription